ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,249.66
0.31%
Dow Jones
42,706.56
-0.06%
Gold vs US Dollar
2,636.44
-0.18%
Brent Oil
76.035
-0.61%
Bitcoin
101,790.65
3.52%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) News

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CALT
DateTimeSourceHeadlineSymbolCompany
23/09/202420:44Edgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:CALTCalliditas Therapeutics AB
16/09/202413:46PR Newswire (US)Delisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmNASDAQ:CALTCalliditas Therapeutics AB
03/09/202411:13PR Newswire (US)Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
03/09/202410:33PR Newswire (US)Calliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiNASDAQ:CALTCalliditas Therapeutics AB
03/09/202410:31PR Newswire (US)Calliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiNASDAQ:CALTCalliditas Therapeutics AB
13/08/202405:25PR Newswire (US)Calliditas Interim Report January to June 2024NASDAQ:CALTCalliditas Therapeutics AB
13/08/202405:22PR Newswire (US)Calliditas Interim Report January to June 2024NASDAQ:CALTCalliditas Therapeutics AB
05/08/202405:26PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - June 2024NASDAQ:CALTCalliditas Therapeutics AB
05/08/202405:19PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - June 2024NASDAQ:CALTCalliditas Therapeutics AB
01/08/202413:00GlobeNewswire Inc.Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership ConferenceNASDAQ:CALTCalliditas Therapeutics AB
31/07/202412:23PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsNASDAQ:CALTCalliditas Therapeutics AB
26/07/202420:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
26/07/202415:23PR Newswire (US)Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyNASDAQ:CALTCalliditas Therapeutics AB
26/07/202415:21PR Newswire (US)Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyNASDAQ:CALTCalliditas Therapeutics AB
26/07/202406:29PR Newswire (US)Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisNASDAQ:CALTCalliditas Therapeutics AB
26/07/202406:23PR Newswire (US)Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisNASDAQ:CALTCalliditas Therapeutics AB
04/07/202407:44PR Newswire (US)Launch of Phase 3 clinical trial with Nefecon in JapanNASDAQ:CALTCalliditas Therapeutics AB
04/07/202407:20PR Newswire (US)Launch of Phase 3 clinical trial with Nefecon in JapanNASDAQ:CALTCalliditas Therapeutics AB
18/06/202410:25PR Newswire (US)Calliditas provides setanaxib patent updateNASDAQ:CALTCalliditas Therapeutics AB
18/06/202410:23PR Newswire (US)Calliditas provides setanaxib patent updateNASDAQ:CALTCalliditas Therapeutics AB
17/06/202416:01PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
30/05/202420:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
30/05/202418:20PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
30/05/202418:18PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
28/05/202412:46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202412:36PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202412:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
28/05/202412:09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202407:17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
28/05/202407:14PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT

Your Recent History

COIN
ORCUSD
Orbit Chain
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads